Topographically guided laser in situ keratomileusis for myopia using a customized aspherical treatment zone.
OBJECTIVE
To assess the efficacy, predictability, safety, and quality-of-life effects of topography-guided laser in situ keratomileusis (LASIK) for the correction of myopia with astigmatism using the EC-5000 CXII excimer laser equipped with a customized aspheric treatment zone algorithm.


METHODS
Ophthalmology clinics in the United States and Mexico.


METHODS
In a multicenter United States Food and Drug Administration study of topography-guided LASIK, 4 centers enrolled 135 eyes with a spherical manifest refraction error ranging from -0.50 to -7.00 diopters (D) and astigmatism ranging from 0.50 to 4.00 D. All eyes were targeted for emmetropia. Refractive outcomes, higher-order aberrations (HOAs), and contrast sensitivity were analyzed preoperatively and postoperatively. Patient satisfaction was assessed using 2 questionnaires.


RESULTS
Six months postoperatively, the mean manifest refraction spherical equivalent in all eyes was -0.09 D +/- 0.31 (SD); of the 131 eyes, 116 (88.55%) had an uncorrected visual acuity of 20/20 or better and 122 (93.13%) had an MRSE within +/-0.50 D. The best spectacle-corrected visual acuity (BSCVA) increased by 2 or more lines in 21 (16.03%) of 131 eyes; no eye lost 2 lines or more of BSCVA. The total ocular HOA increased by 0.04 microm. Patients reported significantly fewer night driving and glare/halo symptoms postoperatively than preoperatively.


CONCLUSIONS
Use of a customized aspherical treatment zone in eyes with myopia and astigmatism was safe, effective, and predictable and reduced symptoms associated with night driving, glare, and halos.
Dougherty
Paul J
PJ
Private Practice, Camarillo, Los Angeles, California, USA. lasikmd2020@yahoo.com
Waring
George
G
Chayet
Arturo
A
Fischer
Jeffery
J
Fant
Barbara
B
Bains
Harkaran S
HS
D000328:Adult; D001251:Astigmatism / Q000150:complications / Q000503:physiopathology / Q000601:surgery; D015350:Contrast Sensitivity / Q000502:physiology; D019781:Corneal Topography / Q000379:methods*; D006801:Humans; D007431:Intraoperative Complications; D020731:Keratomileusis, Laser In Situ / Q000379:methods*; D054018:Lasers, Excimer / Q000627:therapeutic use*; D008875:Middle Aged; D009216:Myopia / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D017060:Patient Satisfaction; D011183:Postoperative Complications; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014792:Visual Acuity / Q000502:physiology